Zeiser

Department of Medicine I
Phone: 0049-761-270-34580
robert.zeiser@uniklinik-freiburg.de
www.uniklinik-freiburg.de/medizin1/forschung

1995-2001 Medical School of University of Freiburg, Tel Aviv and South Florida
2001-2004 Residency and Fellowship in Medicine, Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg
2005-2007 Postdoctoral Research Fellow at the Department of BMT (Prof. Negrin) at Stanford University, Stanford, USA
2010 Postdoctoral thesis (Habilitation) in Internal Medicine, University of Freiburg; Senior physician
2013 Full Professor (W3), Heisenberg
2016 Head of the Section of Tumor immunology, Medical Center – Univ. of Freiburg
2019 Director of the Division of Tumor immunology, Medical Center – Univ. of Freiburg
2021 Speaker of CRC 1479 “Oncogene driven immune escape”

Zeiser R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. The New England Journal of Medicine 385(3):228-238, 2021
Uhl F, (…) Zeiser R. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Science Translational Medicine 12(567): eabb8969, 2020
Zeiser R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. The New England Journal of Medicine 382: 1800-1810, 2020
Mathew NR (…) Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nature Medicine 24: 282-291, 2018
Schwab L, ( ...) Zeiser R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nature Medicine 2014; 20:648-54.
Wilhelm K, (…) Zeiser R. Graft-versus-host disease is enhanced by extracellular ATP activating P2X(7)R. Nature Medicine 2010; 16:1434-8.